Recent Finacing
Recent Raise
Allena Pharmaceuticals develops non-systemic oral protein therapeutics that act in the GI tract; lead program ALLN-177 is an orally administered recombinant oxalate-degrading enzyme in clinical development for hyperoxaluria.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
